Prosecution Insights
Prosecution Insights
148 pending office actions • 64 clients • 131 examiners • 63 art units • 0 of 148 (0%) have an AI response strategy ready • 168 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 148 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 148 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 95 (64%) |
| §102 only | 12 (8%) |
| §112 only | 14 (9%) |
| Double-patenting only | 1 (1%) |
| Double-patenting + other | 2 (1%) |
| No statute on record | 24 (16%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 3 | 47.9% | +16.8% |
| RONEY, CELESTE A | 2 | 62.3% | +18.0% |
| SALMON, KATHERINE D | 2 | 42.6% | +38.0% |
| RYAN, DOUGLAS CHARLES | 2 | 40.0% | +48.9% |
| SZNAIDMAN, MARCOS L | 2 | 36.9% | +15.9% |
| GRABER, JAMES J | 2 | 46.2% | +56.1% |
| GIBBS, TERRA C | 2 | 64.1% | +10.6% |
| SULLIVAN, STEPHANIE LAUREN | 2 | 60.9% | +38.7% |
| STEELE, AMBER D | 2 | 59.1% | +9.1% |
| LIPPERT, JOHN WILLIAM | 2 | 55.7% | +42.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | SALMON, KATHERINE D | 161d overdue |
| 18540656 | NEUROPROTECTIVE LIPOSOME COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE | RONEY, CELESTE A | 72d overdue |
| 18005562 | ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) | QIAN, CELINE X | 51d overdue |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | QIAN, CELINE X | 51d overdue |
| 17759479 | HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR | QIAN, CELINE X | 37d overdue |
| 17999299 | GRANULES FOR 3D PRINTING TECHNOLOGY | SZNAIDMAN, MARCOS L | 30d overdue |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | SALMON, KATHERINE D | 28d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1635 | 9 |
| 1637 | 6 |
| 1615 | 5 |
| 1612 | 5 |
| 1658 | 5 |
| 1631 | 5 |
| 1681 | 5 |
| 1618 | 5 |
| 1632 | 4 |
| 1617 | 4 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18873924 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | The Board Of Regents Of The University Of Oklahoma | MCCULLOUGH, ERIC J. | 1773 | §103 | Non-Final OA | 42d overdue | Pending | Dec 11, 2024 |
| 18857661 | MAGNETICALLY STEERABLE CATHETER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KOLKIN, ADAM D. | 3798 | §103 | Final Rejection | 7d | Pending | Oct 17, 2024 |
| 18660178 | METHODS FOR THE LONG-TERM EXPANSION OF GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA | WESTON, ALYSSA G | 1633 | Other | Non-Final OA | 46d overdue | Pending | May 09, 2024 |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GEMBEH, SHIRLEY V | 1615 | §103 | Non-Final OA | 70d | Pending | Apr 26, 2024 |
| 18698615 | COMPOSITE COATING, PREPARATION METHOD, AND DEVICE | Jiangsu Favored Nanotechnology Co., Ltd. | MILLER, BETHANY MACKENZIE | 1787 | §103 | Non-Final OA | 27d | Pending | Apr 04, 2024 |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | Curevac Manufacturing GmbH | ADAMS, MICHELLE | 1797 | §112 | Non-Final OA | 42d overdue | Pending | Feb 05, 2024 |
| 18427737 | EBOLAVIRUS AND MARBURGVIRUS VACCINES | CUREVAC SE | PARKIN, JEFFREY S | 1671 | §103 | Non-Final OA | 30d overdue | Pending | Jan 30, 2024 |
| 18292366 | IMPROVED DRUG PROCESSING METHODS TO INCREASE DRUG LOADING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SAEED, ALI S | 1616 | Other | Non-Final OA | 10d overdue | Pending | Jan 26, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC SE | BERTOGLIO, VALARIE E | 1632 | §103 | Final Rejection | 11d overdue | Pending | Jan 17, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Research Development Foundation | PAGUIO FRISING, MICHELLE F | 1651 | DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
| 18571920 | HIGH-THROUGHPUT PREPARATION OF MICROPARTICLES WITH PULSATILE RELEASE | William Marsh Rice University | TIEN, LUCY MINYU | 1612 | §103 | Non-Final OA | 75d | Pending | Dec 19, 2023 |
| 18540656 | NEUROPROTECTIVE LIPOSOME COMPOSITIONS AND METHODS FOR TREATMENT OF STROKE | The Board Of Regents Of The University Of Texas System | RONEY, CELESTE A | 1612 | §103 | Non-Final OA | 72d overdue | Pending | Dec 14, 2023 |
| 18522220 | HDL MIMICKING TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF SOLID TUMORS | University of North Texas Health Science Center | MOSHER, ERIC PARKER | 1612 | Other | Non-Final OA | 55d | Pending | Nov 28, 2023 |
| 18518819 | FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME | AustinPx, LLC | ALLEY, GENEVIEVE S | 1617 | Other | Final Rejection | 22d | Pending | Nov 24, 2023 |
| 18563234 | AMINO ACIDS BEARING A TETRAZINE MOIETY | Valanx Biotech GmbH | COPPINS, JANET L | 1628 | §112 | Non-Final OA | 84d | Pending | Nov 21, 2023 |
| 18514277 | STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY | David M. Jackson | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | 49d overdue | Pending | Nov 20, 2023 |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | William Marsh Rice University | SALMON, KATHERINE D | 1682 | §102 | Non-Final OA | 28d overdue | Pending | Oct 27, 2023 |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | CUREVAC SE | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 12d | Pending | Sep 29, 2023 |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Musc Foundation For Research Development | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SALMON, KATHERINE D | 1682 | §103 | Final Rejection | 161d overdue | Pending | Sep 07, 2023 |
| 18548413 | COLLAGENOUS EXTRACTS FOR USE AS A MEDICAMENT | Jellagen Ltd. | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | 24d overdue | Pending | Aug 30, 2023 |
| 18547687 | METHODS FOR POLYPEPTIDE PROCESSING AND ANALYSIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 17d overdue | Pending | Aug 23, 2023 |
| 18547408 | MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS | The Board Of Regents Of The University Of Texas System | BOWERS, NATHAN ANDREW | 1799 | §103 | Final Rejection | 62d | Pending | Aug 22, 2023 |
| 18449100 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD | Fujifilm Cellular Dynamics, Inc. | GRABER, JAMES J | 1631 | Other | Non-Final OA | 27d | Pending | Aug 14, 2023 |
| 18546141 | LOW INTENSITY ULTRASOUND COMBINATION CANCER THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MACFARLANE, STACEY NEE | 1675 | §103 | Non-Final OA | 26d | Pending | Aug 11, 2023 |
| 18365991 | Weight Loss Regimen | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ANGELL, JON E | 1637 | Other | Non-Final OA | 54d | Pending | Aug 05, 2023 |
| 18264413 | INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES | The Board Of Regents Of The University Of Texas System | O DELL, DAVID K | 1621 | §112 | Non-Final OA | 53d | Pending | Aug 04, 2023 |
| 18364809 | PCR DETECTION OF SMALL FRAGMENTS OF A KNOWN NUCLEIC ACID TARGET | VANDERBILT UNIVERSITY | HORLICK, KENNETH R | 1681 | §103 | Non-Final OA | 103d overdue | Pending | Aug 03, 2023 |
| 18264143 | COMPOSITIONS AND METHODS FOR TREATMENT OF HIDRADENITIS SUPPURATIVA | Suzhou Kintor Pharmaceuticals, Inc. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | 15d | Pending | Aug 03, 2023 |
| 18261983 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | BAYLOR COLLEGE OF MEDICINE | DUNN, LINDSAY MICHELLE | 1644 | §103 | Non-Final OA | 17d overdue | Pending | Jul 18, 2023 |
| 18272449 | DEVICE AND METHOD FOR THE SECURE PROCESSING OF DATA | Real-Cis GmbH | SWEARINGEN, JEFFREY R | 2445 | §102 | Final Rejection | 37d overdue | Pending | Jul 14, 2023 |
| 18271991 | APPLICATION OF CILOSTAZOL-CONTAINING COMPOSITION IN PREPARING DRUG FOR TREATING CEREBROVASCULAR DISEASE | Neurodawn Pharmaceutical Co., Ltd. | SCHMITT, MICHAEL J | 1629 | §103 | Non-Final OA | 71d | Pending | Jul 12, 2023 |
| 18271294 | DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT | Seoul National University R&Db Foundation | RAHMAN, MASUDUR | 1633 | §103 | Non-Final OA | 27d | Pending | Jul 07, 2023 |
| 18271131 | SPRAY-TYPE HYDROGEL | Seoul National University R&Db Foundation | GULLEDGE, BRIAN M | 1699 | §103 | Non-Final OA | 3d overdue | Pending | Jul 06, 2023 |
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | Dongguk University Industry-Academic Cooperation Foundation | GIBBS, TERRA C | 1635 | §112 | Non-Final OA | 20d | Pending | Jul 05, 2023 |
| 18270476 | ORAL SOLID FORMULATION FOR COLON CLEANSING | Taejoon Pharmaceutical Co., Ltd. | ATKINSON, JOSHUA ALEXANDER | 1612 | Other | Final Rejection | 8d overdue | Pending | Jun 29, 2023 |
| 18270028 | 2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Kunheng Pharma-Tech Co., Ltd. | HEITMEIER, KENDALL NICOLE | 1621 | Other | Non-Final OA | 26d | Pending | Jun 28, 2023 |
| 18335990 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | The Board Of Regents Of The University Of Texas System | VANHORN, ABIGAIL LOUISE | 1636 | Other | Non-Final OA | 9d overdue | Pending | Jun 15, 2023 |
| 18332603 | METHODS OF TREATING AND PREVENTING ENDOTHELIAL DYSFUNCTION USING BARDOXOLONE METHYL OR ANALOGS THEREOF | Reata Pharmaceuticals Holdings, LLC | MOU, LIYUAN | 1628 | Other | Non-Final OA | 157d overdue | Pending | Jun 09, 2023 |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | Research Development Foundation | BUTTICE, AUDREY L | 1647 | §103 | Non-Final OA | 28d overdue | Pending | Jun 09, 2023 |
| 18256545 | METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS | Reata Pharmaceuticals Holdings, LLC | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | 14d | Pending | Jun 08, 2023 |
| 18265780 | EXHAUST GAS FILTERING APPARATUS AND COATING EQUIPMENT | Jiangsu Favored Nanotechnology Co., Ltd. | HAQ, WASIQUL | 1717 | §103 | Non-Final OA | 8d overdue | Pending | Jun 07, 2023 |
| 18254261 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics | PECKHAM, RICHARD GRANT | 1627 | §103 | Non-Final OA | 33d | Pending | May 24, 2023 |
| 18038181 | DIRECT LYSIS APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | Nuclein, LLC | NGUYEN, HENRY H | 1758 | §103 | Non-Final OA | 82d | Pending | May 22, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | CUREVAC SE | SULLIVAN, STEPHANIE LAUREN | 1635 | DPOther | Non-Final OA | 62d | Pending | May 19, 2023 |
| 18253755 | USE OF MICROVIRIN IN THE IDENTIFICATION OF MYCOBACTERIUM TUBERCULOSIS MANNOSE-CAPPED LIPOARABINOMANNAN | UNIVERSITY OF CAPE TOWN | DEVI, SARVAMANGALA | 1645 | — | Non-Final OA | 14d | Pending | May 19, 2023 |
| 18253687 | USE OF MATURE MITOCHONDRIAL TRANSCRIPTION FACTOR A (TFAM) FOR DIAGNOSING ORGAN DYSFUNCTIONS | Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | 29d | Pending | May 19, 2023 |
| 18036488 | SALICYLIC ACID-INDUCIBLE GENE EXPRESSION COMPOSITIONS AND SYSTEMS FOR CELLS | UNIVERSITY OF HOUSTON SYSTEM | LEONARD, ARTHUR S | 1631 | §103 | Non-Final OA | 27d | Pending | May 11, 2023 |
| 18252185 | METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION | National University Of Singapore | BAUSCH, SARAE L | 1699 | §102 | Non-Final OA | 28d | Pending | May 08, 2023 |
| 18250645 | MUTANT PROTEASES AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MARTIN, RACHEL E | 1657 | §112 | Non-Final OA | 20d | Pending | Apr 26, 2023 |
| 18250532 | DIRECTIONAL AND SCALABLE ELECTRODE ARRAY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PORTER, JR, GARY A | 3796 | §103 | Final Rejection | 16d overdue | Pending | Apr 25, 2023 |
| 18306038 | ICOS TARGETING FOR NEUROPATHIC PAIN RELIEF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | TRAN HO, LAM THUY VI | 1647 | §103 | Non-Final OA | 9d overdue | Pending | Apr 24, 2023 |
| 18249647 | ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES | Avecho Biotechnology Limited | KUCHARCZK, JED A | 1623 | Other | Non-Final OA | 2d overdue | Pending | Apr 19, 2023 |
| 18031793 | USE OF MICROORGANISMS AND CALCIUM FOR IMPROVED PLANT HELATH AND/OR RESILIENCE AGAINST PLANT PATHOGENS | Valibiotics GmbH | UNDERDAHL, THANE E | 1699 | §103 | Final Rejection | 35d overdue | Pending | Apr 13, 2023 |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | CUREVAC SE | SHIN, DANA H | 1635 | Other | Non-Final OA | 58d overdue | Pending | Mar 13, 2023 |
| 18044877 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | 16d overdue | Pending | Mar 10, 2023 |
| 18044668 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | STEELE, AMBER D | 1658 | §103 | Non-Final OA | 15d overdue | Pending | Mar 09, 2023 |
| 18180377 | METHODS FOR OBTAINING MUSCLE DERIVED CELLS | Innovacell AG | JOHNSON, KARA D | 1632 | §103 | Non-Final OA | 43d overdue | Pending | Mar 08, 2023 |
| 18178368 | DIRECT METHOD OF SYNTHESIS OF ZNO NWS/SWCNTS AND ZNO NWS/GRAPHENE HETEROSTRUCTURES | Saint Louis University | WALTERS JR, ROBERT S | 1717 | §103 | Final Rejection | 19d | Pending | Mar 03, 2023 |
| 18043577 | MANUFACTURING DEVICE FOR A PHARMACEUTICAL PRODUCT | Tesla Automation GmbH | SHI, TINGCHEN | 1796 | §103 | Non-Final OA | 12d | Pending | Feb 28, 2023 |
| 18042390 | FUNCTIONAL IONIZABLE PHOSPHOLIPIDS | The Board Of Regents Of The University Of Texas System | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 65d | Pending | Feb 21, 2023 |
| 18041811 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | RONEY, CELESTE A | 1612 | §103 | Final Rejection | 16d | Pending | Feb 16, 2023 |
| 18041470 | TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | §103 | Non-Final OA | 21d | Pending | Feb 13, 2023 |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | CUREVAC SE | WU, JULIE ZHEN QIN | 1643 | §103 | Non-Final OA | 93d overdue | Pending | Jan 30, 2023 |
| 18018866 | TOTAL SYNTHESES OF SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS), STRUCTURAL ISOMERS AND STRUCTURAL ANALOGS | UNIVERSITE LAVAL | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | 70d | Pending | Jan 30, 2023 |
| 18018518 | BROAD-SPECTRUM ANTIVIRAL DRUG FOR ENTEROVIRUS, AND APPLICATION | Wuhan Institute Of Virology, Chinese Academy Of Sciences | COFFA, SERGIO | 1658 | §102 | Final Rejection | 70d | Pending | Jan 27, 2023 |
| 18017669 | USE OF PERLECAN AND FRAGMENTS THEREOF TO REDUCE THE RISK OF DEATH IN STROKE PATIENTS | Stream Biomedical, Inc. | STEELE, AMBER D | 1658 | §102 | Non-Final OA | 28d overdue | Pending | Jan 23, 2023 |
| 18005562 | ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) | Xyone Therapeutics, Inc. | QIAN, CELINE X | 1637 | §102 | Non-Final OA | 51d overdue | Pending | Jan 13, 2023 |
| 18016275 | ANTIBODY DRUG CONJUGATE INTERMEDIATE CONTAINING SN38 AND ITS PREPARATION METHOD | Mabplex International Co., Ltd. | SKOKO III, JOHN JOSEPH | 1643 | §103 | Non-Final OA | 83d | Pending | Jan 13, 2023 |
| 18014746 | SUPER HYDROPHOBIC FILM LAYER, PREPARATION METHOD THEREOF,AND PRODUCT THEREOF | Jiangsu Favored Nanotechnology Co., Ltd. | EMPIE, NATHAN H | 1712 | §103 | Non-Final OA | 6d | Pending | Jan 06, 2023 |
| 18003412 | AMPLICON COMPREHENSIVE ENRICHMENT | William Marsh Rice University | BERTAGNA, ANGELA MARIE | 1681 | §103 | Non-Final OA | 3d overdue | Pending | Dec 27, 2022 |
| 18146038 | LATERAL FLOW DETECTION DEVICE FOR ACUTE AORTIC SYNDROME | Pericard Check GmbH | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 96d overdue | Pending | Dec 23, 2022 |
| 18011073 | IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS | The Heart Research Institute Ltd. | DESAI, ANAND U | 1655 | §103 | Non-Final OA | 70d overdue | Pending | Dec 16, 2022 |
| 18001411 | 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BROWE, DAVID | 1617 | Other | Final Rejection | 25d overdue | Pending | Dec 09, 2022 |
| 18008134 | MODEL FOR PREDICTION OF TOLERABILITY ISSUES IN CONNECTION WITH INTRAVENOUS ADMINISTRATION OF THERAPEUTIC ANTIBODIES | Bioinvent International AB | HALVORSON, MARK | 1646 | §103 | Non-Final OA | 63d | Pending | Dec 02, 2022 |
| 18060134 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF BONE DISORDERS | Research Development Foundation | FAN, LYNN Y | 1759 | §103 | Final Rejection | 79d overdue | Pending | Nov 30, 2022 |
| 18060183 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | Research Development Foundation | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | 17d overdue | Pending | Nov 30, 2022 |
| 18000183 | Treatment Of Homocystinuria And Hyperhomocysteinemia Using Cystathionine-Gamma-Lyase | The Board Of Regents Of The University Of Texas System | CURRENS, GRANT CARSON | 1651 | Other | Final Rejection | 6d | Pending | Nov 29, 2022 |
| 17999735 | ADAPTER MOLECULES TO RE-DIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST | UNIVERSITY OF ZURICH | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | 79d overdue | Pending | Nov 23, 2022 |
| 17999400 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | Servier Pharmaceuticals LLC | OLSON, ANDREA STEFFEL | 1693 | §103 | Non-Final OA | 5d overdue | Pending | Nov 20, 2022 |
| 17999299 | GRANULES FOR 3D PRINTING TECHNOLOGY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SZNAIDMAN, MARCOS L | 1628 | §103 | Final Rejection | 30d overdue | Pending | Nov 18, 2022 |
| 17998194 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | Research Development Foundation | OGUNBIYI, OLUWATOSIN A | 1645 | Other | Non-Final OA | 36d overdue | Pending | Nov 08, 2022 |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Research Development Foundation | LI, RUIXIANG | 1674 | §112 | Final Rejection | 77d overdue | Pending | Nov 03, 2022 |
| 17997696 | QUANTITATIVE BLOCKER DISPLACEMENT AMPLIFICATION (QBDA) SEQUENCING FOR CALIBRATION-FREE AND MULTIPLEXED VARIANT ALLELE FREQUENCY QUANTITATION | William Marsh Rice University | PRIEST, AARON A | 1681 | Other | Non-Final OA | 43d overdue | Pending | Nov 01, 2022 |
| 17997453 | ALBUMIN DRUG CONJUGATES AND USE THEREOF FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LEE, JAE W | 1656 | §103 | Non-Final OA | 9d overdue | Pending | Oct 28, 2022 |
| 17996618 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | 14d | Pending | Oct 19, 2022 |
| 17938003 | KRATOM OPIOID DERIVATIVES FOR THE TREATMENT OF ALCOHOL USE DISORDER | The Trustees of Columbia University in the City of New York | MOORE, SUSANNA | 1624 | §103 | Non-Final OA | 28d | Pending | Oct 04, 2022 |
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | The Children's Hospital of Philadelphia | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 111d overdue | Pending | Oct 04, 2022 |
| 17995214 | CD5L-BINDING ANTIBODIES AND USES FOR THE SAME | The Board Of Regents Of The University Of Texas System | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §112 | Non-Final OA | 3d overdue | Pending | Sep 30, 2022 |
| 17907386 | FOOD COLOURING AGENTS | V2Food Pdy Ltd. | DIVIESTI, KARLA ISOBEL | 1792 | §112 | Non-Final OA | 23d | Pending | Sep 26, 2022 |
| 17931669 | METHODS FOR THE PRODUCTION OF COMMITTED CARDIAC PROGENITOR CELLS | Fujifilm Cellular Dynamics, Inc. | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Final Rejection | 62d | Pending | Sep 13, 2022 |
| 17820277 | DIGITAL AMPLIFICATION ASSAY ANALYSIS METHOD | Luminex Corporation | KIM, YOUNG J | 1681 | Other | Final Rejection | 8d overdue | Pending | Aug 17, 2022 |
| 17819268 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | HOERNER, PAUL ELLSWORTH | 1611 | Other | Final Rejection | 4d overdue | Pending | Aug 11, 2022 |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | Cancer Research Technology Limited | OUSPENSKI, ILIA I | 1644 | DPOther | Non-Final OA | 77d | Pending | Aug 11, 2022 |
| 17819259 | DRY POWDER COMPOSITIONS OF OIL-IN-WATER (O/W) EMULSION ADJUVANTED VACCINES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | LI, BAO Q | 1671 | §103 | Final Rejection | 99d overdue | Pending | Aug 11, 2022 |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | QIAN, CELINE X | 1637 | §103 | Non-Final OA | 51d overdue | Pending | Aug 10, 2022 |
| 17815711 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | UNIVERSITY OF SOUTHERN CALIFORNIA | KONOPKA, CATHERINE ANNE | 1635 | §103 | Non-Final OA | 31d overdue | Pending | Jul 28, 2022 |
| 17759479 | HUMAN ANTI-DENGUE ANTIBODIES AND METHODS OF USE THEREFOR | The Regebts Of The University Of California A California | QIAN, CELINE X | 1637 | §112 | Non-Final OA | 37d overdue | Pending | Jul 26, 2022 |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA | GIBBS, TERRA C | 1635 | §103 | Non-Final OA | 72d | Pending | Jul 22, 2022 |
| 17862090 | Systems and Methods for Recovering Lithium from Brines Field | Energy Exploration Technologies, Inc. | MENDEZ, ZULMARIAM | 1794 | §102 | Final Rejection | 32d overdue | Pending | Jul 11, 2022 |
| 17808180 | METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSIS | Luminex Corporation | SISSON, BRADLEY L | 1682 | Other | Final Rejection | 56d | Pending | Jun 22, 2022 |
| 17782314 | A BIOMARKER AND USES THEREFOR | Perron Institute For Neurological And Translational Science Limited | KAPUSHOC, STEPHEN THOMAS | 1683 | §112 | Non-Final OA | 32d overdue | Pending | Jun 03, 2022 |
| 17782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | §103 | Non-Final OA | 39d | Pending | Jun 02, 2022 |
| 17777102 | INCLUSION COMPLEXES OF PHARMACEUTICALS AND CYCLIC OLIGOMERS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MEYERS, ELIZABETH ANNE | 1617 | §103 | Final Rejection | 55d | Pending | May 16, 2022 |
| 17774848 | METHOD FOR PRODUCING CYTOTOXIC EFFECTOR MEMORY T-CELLS FOR CAR T-CELL TREATMENT OF CANCER | BAYLOR COLLEGE OF MEDICINE | HILL, KEVIN KAI | 1638 | §103 | Final Rejection | 3d overdue | Pending | May 05, 2022 |
| 17769323 | COMPOUNDS FOR TARGETED DEGRADATION OF CARRIER PROTEINS AND USES THEREOF | Cemm - Forschungszentrum Für Molekulare Medizin GmbH | RAO, PADMAJA S | 1627 | §112 | Non-Final OA | 110d overdue | Pending | Apr 14, 2022 |
| 17698906 | COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS TO TREAT LUNG DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 28d overdue | Pending | Mar 18, 2022 |
| 17693062 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | Tff Pharmaceuticals, Inc. | GOTFREDSON, GAREN | 1619 | §103 | Final Rejection | 60d overdue | Pending | Mar 11, 2022 |
| 17630887 | ADENOSINE RECEPTOR ANTAGONIST | Xiamen Biotime Biotechnology Co., Ltd. | MAHLUM, JONATHAN DAVIS | 1625 | §102 | Non-Final OA | 126d overdue | Pending | Jan 27, 2022 |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | Curevac AG | LEITH, NANCY J | 1636 | Other | Non-Final OA | 30d | Pending | Jan 14, 2022 |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | BAYLOR COLLEGE OF MEDICINE | JUEDES, AMY E | 1644 | Other | Final Rejection | 132d overdue | Pending | Jan 14, 2022 |
| 17567868 | METHODS FOR PREDICTING KINASE INHIBITOR RESISTANCE | Research Development Foundation | DESAI, ANAND U | 1655 | §103 | Final Rejection | 24d overdue | Pending | Jan 03, 2022 |
| 17620047 | ROTAVIRUS MRNA VACCINE | Curevac AG | GRABER, JAMES J | 1631 | §102 | Final Rejection | 8d overdue | Pending | Dec 16, 2021 |
| 17596622 | USE OF SRRD IN THE INHIBITION OF PROTEIN AGGREGATION | The Children's Hospital of Philadelphia | WANG, CHANG YU | 1675 | §112 | Final Rejection | 28d overdue | Pending | Dec 14, 2021 |
| 17619096 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | Fujifilm Holdings America Corporation | BEHARRY, ZANNA MARIA | 1632 | §102 | Non-Final OA | 8d overdue | Pending | Dec 14, 2021 |
| 17548467 | SYSTEMS AND METHODS FOR LASER-INDUCED CALCIUM FRACTURES | Research Development Foundation | ANJARIA, SHREYA PARAG | 3796 | §103 | Final Rejection | 134d overdue | Pending | Dec 10, 2021 |
| 17616542 | FORMING OF DISINFECTANT SOLUTIONS | Control Chemicals (Pty) Ltd. | PATEL, PRANAV N | 1777 | §103 | Non-Final OA | 45d overdue | Pending | Dec 03, 2021 |
| 17614638 | pH RESPONSIVE COMPOSITIONS AND USES THEREOF | The Board Of Regents Of The University Of Texas System | ROGERS, JAMES WILLIAM | 1618 | §103 | Final Rejection | 79d overdue | Pending | Nov 29, 2021 |
| 17529492 | Systems and Methods for Recovering Lithium from Brines Field | Energy Exploration Technologies, Inc. | MENDEZ, ZULMARIAM | 1794 | §112 | Final Rejection | 22d | Pending | Nov 18, 2021 |
| 17607837 | MICRO-RNA SITE BLOCKING OLIGONUCLEOTIDES FOR THE TREATMENT OF EPILEPTIC ENCEPHALOPATHY AND NEURODEVELOPMENTAL DISORDERS | The Trustees of the University of Pennsylvania | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Non-Final OA | 6d | Pending | Oct 29, 2021 |
| 17594651 | CRISPR/CAS9 GENE EDITING OF ATXN2 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 2 | The Children's Hospital of Philadelphia | BABIC, CHRISTOPHER M | 1633 | §103 | Non-Final OA | 8d overdue | Pending | Oct 25, 2021 |
| 17604689 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MAHLUM, JONATHAN DAVIS | 1625 | §102 | Final Rejection | 120d overdue | Pending | Oct 18, 2021 |
| 17604560 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Non-Final OA | 12d | Pending | Oct 18, 2021 |
| 17604305 | COMPOUNDS AND METHODS FOR IMAGING IMMUNE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 56d overdue | Pending | Oct 15, 2021 |
| 17600600 | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Final Rejection | 19d overdue | Pending | Sep 30, 2021 |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SKOKO III, JOHN JOSEPH | 1643 | §103 | Final Rejection | 27d | Pending | Sep 27, 2021 |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | Curevac AG | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 73d overdue | Pending | Aug 06, 2021 |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | Curevac AG | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | 81d overdue | Pending | Jul 19, 2021 |
| 17346563 | SYSTEMS AND METHODS FOR IMAGING AND MANIPULATING TISSUE | Research Development Foundation | HUH, VYNN V | 3792 | §103 | Non-Final OA | 45d overdue | Pending | Jun 14, 2021 |
| 17295747 | METHODS OF OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | STONEBRAKER, ALYSSA RAE | 1642 | §103 | Final Rejection | 46d overdue | Pending | May 20, 2021 |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | The Children's Hospital of Philadelphia | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 30d overdue | Pending | Apr 29, 2021 |
| 17235771 | BIOLOGICALLY ACTIVE DRY POWDER COMPOSITIONS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | NGUYEN, JOHN P | 1619 | §103 | Non-Final OA | 17d overdue | Pending | Apr 20, 2021 |
| 17276032 | COMBINATION CANCER THERAPIES | The Board Of Regents Of The University Of Oklahoma | ELENISTE, PIERRE PAUL | 1622 | §103 | Non-Final OA | 74d overdue | Pending | Mar 12, 2021 |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | The Children's Hospital of Philadelphia | REGA, KYLE THOMAS | 1636 | §103 | Non-Final OA | 16d | Pending | Feb 26, 2021 |
| 17180816 | MANIPULATING THE CIRCADIAN CLOCK TO INCREASE GENE EXPRESSION | VANDERBILT UNIVERSITY | SHARMA, SANTOSH | 1663 | §103 | Final Rejection | 92d overdue | Pending | Feb 21, 2021 |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | The Children's Hospital of Philadelphia | MCLEOD, AFRICA MHAIRIE | 1635 | Other | Final Rejection | 8d overdue | Pending | Feb 02, 2021 |
| 17146912 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM | Grifols Shared Services North America, Inc. | BEANE, RANDALL L | 1654 | §102 | Final Rejection | 28d | Pending | Jan 12, 2021 |
| 16972259 | DETECTION OF IMMUNE CHECKPOINT MOLECULES BY DEGLYCOSYLATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RAMADAN, OMAR | 1678 | §103 | Non-Final OA | 19d overdue | Pending | Dec 04, 2020 |
| 17054312 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | William Marsh Rice University | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 12d | Pending | Nov 10, 2020 |
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Non-Final OA | 87d overdue | Pending | Oct 15, 2020 |
| 17045535 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH | MIKNIS, ZACHARY J | 1658 | §103 | Final Rejection | 9d | Pending | Oct 06, 2020 |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | Curevac AG | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Non-Final OA | 72d overdue | Pending | Oct 05, 2020 |
| 16933773 | NUCLEIC ACID PURIFICATION | ZYMO RESEARCH CORPORATION | NGUYEN, QUANG | 1631 | §103 | Final Rejection | 100d overdue | Pending | Jul 20, 2020 |
| 16757289 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | Curevac AG | RYAN, DOUGLAS CHARLES | 1635 | Other | Final Rejection | 40d | Pending | Apr 17, 2020 |
| 16757297 | METHODS AND COMPOSITIONS FOR THE PURIFICATION OF UNBIASED RNA | ZYMO RESEARCH CORPORATION | GREENE, CAROLYN LEE | 1681 | §103 | Final Rejection | 9d | Pending | Apr 17, 2020 |
| 16834504 | COMPACT FLUID WARMER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | EKRAMI, YASAMIN | 3794 | §103 | Non-Final OA | 19d overdue | Pending | Mar 30, 2020 |
| 16348115 | AUTOMATED METHOD FOR RELEASE OF NUCLEIC ACIDS FROM MICROBIAL SAMPLES | ZYMO RESEARCH CORPORATION | MISHRA, DEEPA | 1657 | §103 | Non-Final OA | 7d | Pending | May 07, 2019 |
| 16098145 | IMPROVED DRUG FORMULATIONS | AustinPx, LLC | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | 98d overdue | Pending | Nov 01, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial